Analytical studies on ascosin, candicidin and levorin multicomponent antifungal antibiotic complexes. The stereostructure of ascosin A2

Paweł Szczeblewski, Tomasz Laskowski, Bartosz Kubacki, Marta Dziergowska, Magda Liczmańska, Jakub Grynda, Paweł Kubica, Agata Kot-Wasik and Edward Borowski

ELECTRONIC SUPPLEMENTARY INFORMATION

Table of contents:

1. NMR spectra of 3'-N-acetylascosin A2 methyl ester (A2*)	2
2. MS and UV-VIS spectra	8
2.1. UV-VIS spectra	8
2.2. MS spectra	8



1. NMR SPECTRA OF 3'-N-ACETYLASCOSIN A2 METHYL ESTER (A2*).

Figure 1.1. ¹H NMR spectrum of A2*.



Figure 1.2. DQF-COSY spectrum of A2*.



Figure 1.3. TOCSY spectrum of A2*. Mix time = 110 ms.



Figure 1.4. Edited HSQC spectrum of A2*.



Figure 1.5. GHMBC spectrum of A2*.



Figure 1.6. ROESY spectrum of A2*. Mix time = 300 ms.

2. MS AND UV-VIS SPECTRA.

2.1. UV-VIS spectra.



Figure 2.1. The example UV-VIS spectrum of candicidin D recorded with DAD detector. The same UV-Vis spectra were obtained for all major components of studied complexes.



2.2. MS spectra.

Figure 2.2. The high-resolution isotopic mass distribution of pseudomolecular ions [M+H]⁺ of ascosin A1.



Figure 2.3. The high-resolution isotopic mass distribution of pseudomolecular ions [M+H]⁺ of ascosin A2.



Figure 2.4. The high-resolution isotopic mass distribution of pseudomolecular ions [M+H]⁺ of ascosin A3.



Figure 2.5. The high-resolution isotopic mass distribution of pseudomolecular ions [M+H]⁺ of candicidin A1.



Figure 2.6. The high-resolution isotopic mass distribution of pseudomolecular ions [M+H]⁺ of candicidin D.



Figure 2.7. The high-resolution isotopic mass distribution of pseudomolecular ions [M+H]⁺ of candicidin A3.



Figure 2.8. The high-resolution isotopic mass distribution of pseudomolecular ions [M+H]⁺ of levorin A1.



Figure 2.9. The high-resolution isotopic mass distribution of pseudomolecular ions [M+H]⁺ of levorin A2.



Figure 2.10. The high-resolution isotopic mass distribution of pseudomolecular ions [M+H]⁺ of levorin A3.